AGITATION IN DELIRIUM MANAGEMENT MARKET ANALYSIS

Global agitation in delirium management market is estimated to be valued at US$ 237.2 Mn in 2023, and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).

Analysts’ Views on Global Agitation in Delirium Management Market:

Hyperactive delirium is characterized by agitation, increased psychomotor activity, and a heightened level of arousal. It is the most recognizable type but accounts for less than 10% of delirium observed in the emergency department (ED). Hypoactive delirium is the most common type, accounting for approximately 90%. Thus, it offers the opportunity to various manufacturers to offer various drugs for the management of agitation delirium.

Figure 1. Global Agitation in Delirium Management Market Share (%), By Drug Type, 2023

To learn more about this report, request a free sample copy

Global Agitation in Delirium Management Market– Drivers

• Increasing incidence of delirium: The increasing incidence of delirium among patients admitted to intensive care unit (ICU) is expected to drive the global agitation in delirium management market growth over the forecast period. For instance, in September 2022, according to the data published by Hindwai, a a publisher of peer-reviewed, open access, scientific journals currently active in scientific, technical, and medical literature, the incidence of delirium was up to 46.3% among patients admitted to the ICU.

Figure 2. Global Agitation in Delirium Management Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Global Agitation in Delirium Management Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global agitation in delirium management market over the forecast period. North America is estimated to hold 42.0% of the market share in 2023. North America agitation in delirium management market is expected to witness significant growth in the near future due to increasing healthcare expenditures in the region. The increasing prevalence of pulmonary embolism among patients is expected to drive the North America agitation in delirium management market growth over the forecast period. For instance, in U.S., the total health care expenditures associated with delirium are ranged from US$ 38 to US$152 billion each year, including costs associated with readmission, falls, and long-term care and the care costs of one patient with delirium increased their total care cost by about US$ 600 per day and US$ 18,000 over 30 days due to an increase in service use, including bed-related expenses, laboratory and diagnostic radiology costs, and pharmacy costs.

Global Agitation in Delirium Management Market – Impact of Coronavirus (COVID-19) Pandemic

• Since, the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others. faced problems regarding transportation of things from one place to another.
• However, the COVID-19 pandemic had a positive impact on the global agitation in delirium management market. As many hospitalized patients with COVID-19 develop delirium, and given early insights into the pathobiology of this virus indicating invasion into the brain stem, as well as the emerging interventions utilized to treat these critically ill patients, delirium prevention and management may prove exceedingly challenging, especially in the intensive care unit (ICU). Thus, COVID-19 destroys the respiratory tract and invades the central nervous system, both of which produce an extremely high-risk circumstance for both acute and long-term brain dysfunction in patients infected with the COVID-19 virus.

Global Agitation in Delirium Management Market - Segmentation

The global agitation in delirium management market is segmented into drug type, route of administration, distribution channel, and region.

• Based on drug type, the market is segmented into first-generation antipsychotics, second-generation antipsychotics, and benzodiazepines. Out of which, the first-generation antipsychotics segment is expected to hold a dominant position in the global agitation in delirium management market during the forecast period due to increasing product launches by key market players.
• Based on route of administration, the market is segmented into oral, intramuscular and others. Out of which, oral segment is expected to dominate the market over the forecast period due to increasing preference of oral routes of administration for agitation in delirium management.
• Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period due to the increasing number of hospital pharmacies.
• Among all the segmentation, the drug type segment is expected to dominate the market over the forecast period due to increasing product launches by key market players.

Global Agitation in Delirium Management Market - Cross Sectional Analysis

Among drug type segments, first-generation antipsychotics are expected to drive the global agitation in delirium management market over the forecast period due to fewer extrapyramidal side effects. Greater awareness about delirium and availability of new formulations of antipsychotic drugs are boosting. For instance, several educational campaigns by medical associations and non-profit organizations in recent times have highlighted the need for prompt diagnosis and treatment of delirium. Additionally, the market has witnessed the launch of novel long-acting injectable and oral formulations of antipsychotics that claim better tolerability and ensure medication adherence in delirium patients. These advances in formulation and higher acceptability of pharmacological management indicate robust growth opportunities for players in this market over the coming decade.

Global Agitation in Delirium Management Market: Key Developments

In November 2021, British Geriatrics Society, a multidisciplinary professional organisation helping improve healthcare for older people. announced the launch of its Delirium Hub resource, which helps link users to useful, practical and high-quality information on all aspects of delirium in older people. The hub guides users through the topic of delirium, focusing on four key interlinked areas: an introduction to delirium presentation; screening and treatment of delirium in specific settings; education and training; and current research evidence.

Global Agitation in Delirium Management Market: Key Trends

• Increasing product approval by regulatory authority: Increasing product approval by regulatory authority is expected to prpel the market growth. For instance, in June 2021, Alkermes plc, a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved LYBALVI, a combination of olanzapine and samidorphan, for the treatment of adults with schizophrenia or bipolar I disorder. LYBALVI is a once-daily, atypical antipsychotic that works as a maintenance monotherapy for the acute treatment of manic or mixed episodes or as an adjunct to lithium or valproate.   

Global Agitation in Delirium Management Market: Restraint

• High cost of treatment: The high cost of treatment is significantly restraining the growth of the global agitation in delirium management market. For instance, according to a study published by the U.S. National Library of Medicine in 2020, the average daily cost of pharmacotherapy for delirium in the U.S. was US$105. This included the costs of drugs like haloperidol, olanzapine, ziprasidone, and risperidone, which are commonly used to treat agitation in delirium patients. The study analyzed data on pharmacotherapy costs from 1450 patients aged 65 years and older admitted to multiple hospitals in the country. It was reported that antipsychotic medications accounted for over 60% of the total pharmacotherapy costs for delirium management. Given the effective nature of these drugs, their usage is often limited in many healthcare systems worldwide due to budget constraints. Key players are focusing on developing advancing products with safety and cost effective, and this is expected to drive market growth over the forecast period.

Global Agitation in Delirium Management Market - Key Players

Major players operating in the global agitation in delirium management market include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., BioXcel Therapeutics, Inc., and Takeda Pharmaceutical Company Limited

Global Agitation in Delirium Management Market

*Definition: Delirium refers to a state of mental confusion characterized by abrupt ups and downs in consciousness and attention. It is caused by underlying medical conditions such as infections, drug effects or withdrawal, and stress. Agitation often co-occurs with delirium and needs timely management to prevent self-harm and aid recovery. Growing awareness about delirium and agitation care protocols, along with favorable reimbursement for their management, is expected to drive the market during the forecast period.